Drugs /

sintilimab

Back to Drugs List
Associated Genetic Biomarkers

Overview

NCI Definition [1]:
A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, sintilimab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the immunoglobulin (Ig) superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.

Clinical Trials

View Clinical Trials for sintilimab

Sintilimab has been investigated in 13 clinical trials, of which 12 are open and 1 is closed. Of the trials investigating sintilimab, 1 is phase 1 (0 open), 10 are phase 2 (10 open), and 2 are phase 3 (2 open).

EGFR A763_Y764insFQEA, EGFR Codon 719 Missense, and EGFR Exon 19 Deletion are the most frequent biomarker inclusion criteria for sintilimab clinical trials.

Non-small cell lung carcinoma, renal cell carcinoma, and adenocarcinoma of the gastroesophageal junction are the most common diseases being investigated in sintilimab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Sintilimab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Sintilimab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating sintilimab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-pd-1 monoclonal antibody ibi308, ibi308, ibi 308, anti-pdcd1 monoclonal antibody ibi308, sintilimab
Drug Categories [2]:
Anti-PD-1 antibodies
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C132992

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.